small molecule

SERENTIL

MESORIDAZINE BESYLATE

Loss of exclusivity—loss of exclusivity

CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand name	SERENTIL
Active ingredient	MESORIDAZINE BESYLATE
Strength	EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.